1	Relative vaccine effectiveness of a CoronaVac booster dose in preventing symptomatic SARS-CoV-2									
2	infection among healthcare workers during an Omicron period in Azerbaijan, January–August 2022									
3	Iris Finci ¹ *, Madelyn Yiseth Rojas Castro ² *, Nabil Seyidov ³ *, Samir Mehdiyev ³ , C. Jason McKnight ¹ ,									
4	Barbara Mühlemann ^{4,5} , Christian Drosten ^{4,5} , Lindsey Duca ⁶ , Richard Pebody ¹ , Esther Kissling ² , Mark A.									
5	Katz ¹ , Gahraman Hagverdiyev ³									
6	1. World Health Organization Regional Office for Europe, Copenhagen, Denmark									
7	2. Epiconcept, Paris, France									
8	3. Public Health and Reforms Center, Ministry of Health, Azerbaijan Republic									
9	4. Institute of Virology, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität									
10	Berlin, Humboldt- Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany									
11	5. German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany									
12	6. United States Centers for Disease Control and Prevention, Atlanta, GA, United States of America									
13	* These first authors contributed equally to this article									
14										
15	Corresponding author:									
16	Iris Finci									
17	World Health Organization Regional Office for Europe									
18	UN City, Marmorvej 51, 2100 Copenhagen, Denmark									
19	fincii@who.int									
20										
21	Abstract word count: 50									
22	Main text word count: 1180									

23	Key words: Azerbaijan,	CoronaVac,	COVID-19,	healthcare workers,	SARS-CoV-2,	booster, vaccination
----	------------------------	------------	-----------	---------------------	-------------	----------------------

- vaccine effectiveness, BA.1, BA.2, Omicron

Abstract

- Among Azerbaijani healthcare workers (HCWs), compared to primary vaccine series, CoronaVac
- booster relative vaccine effectiveness was 60% (95% CI:25–79) and 79% (95% CI:44–92) against
- symptomatic and medically attended illness, respectively, during an Omicron BA.1/BA.2 period. Our
- results support timely CoronaVac booster uptake among Azerbaijani HCWs to reduce morbidity.

43 Main text

44	COVID-19 vaccination has been critical in reducing COVID-19-related morbidity and mortality (1,2).
45	Vaccinating healthcare workers (HCWs) against COVID-19 is vital for more resilient healthcare systems;
46	HCWs face high SARS-CoV-2 exposure, regularly interact with vulnerable patients, and are essential for
47	the continuous functioning of health services. In Azerbaijan, an upper-middle income country, HCWs
48	have been prioritized for COVID-19 vaccination throughout the vaccination campaign. CoronaVac
49	(CN02 strain, Sinovac, Beijing) has mainly been used. While inactivated vaccines like CoronaVac have
50	been widely used in low- and middle-income countries, including those in the WHO European Region,
51	few studies have evaluated their effectiveness, particularly during the period characterised by
52	circulation of Omicron variants BA.1, BA.2 and BA.4/5 (hereafter 'Omicron period') (3–8).
53	Understanding COVID-19 vaccine effectiveness is essential for guiding vaccine policy. Additionally,
54	having local data showing effectiveness of COVID-19 vaccines can help promote vaccine uptake. Using
55	a prospective cohort of HCWs in Azerbaijan, we previously estimated that vaccine effectiveness (VE) of
56	two-dose primary vaccine series (PVS) against symptomatic SARS-CoV-2 infection was 19% during a
57	Delta-predominant period (9). In this study, we the same cohort to estimate relative VE (rVE) of a
58	CoronaVac booster dose compared to PVS against symptomatic SARS-CoV-2 infection during an
59	Omicron-predominant period.

60

61 The study

This cohort study has been described previously (9,10). Briefly, in mid-2021, we enrolled HCWs from
 seven hospitals in Baku and collected information on sociodemographics, occupational exposure, and
 COVID-19 vaccination status. Participants completed weekly symptom questionnaires, those reporting

any respiratory symptom were tested for SARS-CoV-2 by RT-PCR. We administered guestionnaires to 65 66 PCR-positive participants 30 days post-symptom onset to obtain information about their illness course. 67 Data on vaccination and SARS-CoV-2 PCR testing results were validated using national databases. 68 We restricted the analysis to participants eligible for booster doses according to the Azerbaijan 69 government: those who had received PVS at least five months (150 days) prior. During January 1 - 170 August 31, 2022, we estimated the rVE of a first booster compared to a PVS series against two 71 outcomes: i) symptomatic PCR-confirmed SARS-CoV-2 infection (COVID-19) and ii) medically attended 72 COVID-19, defined as an outpatient visit because of COVID-19. Participants were considered fully 73 vaccinated 14 days after receiving their PVS and 7 days after receiving their booster dose. We assessed 74 the effect of time since vaccination on rVE against symptomatic infection over the time intervals: 7–89. 75 90–150 and \geq 150 days following booster dose. We evaluated rVE during the overall study period and separately for the period in which SARS-CoV-76 77 2 Omicron BA.1 and BA.2 variants were predominantly circulating (January 1–March 31, 2022), which 78 we defined using whole genome sequencing data from study samples and publicly available data from 79 GISAID (Figure S2) (9,11). 80 Relative VE was estimated as (1-adjusted hazard ratio)*100. Hazard ratios comparing vaccinated

and unvaccinated participants were estimated using Cox proportional hazards models with vaccination as a time-varying exposure and a calendar timescale. Hospital location (urban or sub-urban) and previous SARS-CoV-2 infection were included in the model as fixed effects. Additional details about study methods are included in the supplemental material. The study was approved by the Azerbaijan and WHO Research Ethics Review Committees. All study participants provided written informed consent.

87	At the study start, there were 1367 participants (Figure S1). The median age was 48 (IQR: 39–57),
88	and 1276 (93%) were female. Overall, 506 (37%) were nurses, 349 (26%) were physicians, and 512
89	(37%) were other professions. Overall, 375 (27%) had received PVS, 939 (69%) had received a booster,
90	30 (2%) received one vaccine dose, and 23 (2%) remained unvaccinated. Only participants who
91	received CoronaVac vaccine were included in the analysis (Table 1). The median time from receiving
92	the last vaccine dose until the start of follow-up was 66 days (IQR: 56–96) for booster dose and 150
93	days (IQR: 150–187) for PVS. At the study end, 1186 (87%) participants had received a CoronaVac
94	booster dose (Table S1).
95	During the study period, 74 participants (5%) had PCR-confirmed COVID-19, of whom 53 (72%) had
96	been vaccinated with a booster dose and 17 (23%) with PVS. Most cases [66 (89%)] occurred between
97	January and March 2022, mirroring the trends in COVID-19 incidence in Azerbaijan (Figure 1). Among
98	the participants with PCR-confirmed SARS-CoV-2, 24 (32%) sought outpatient medical care. There were
99	no emergency room visits, hospitalisations, or deaths among participants.
100	For the whole analysis period (January–August 2022), the rVE was 59% (95% CI: 24–78) against
101	symptomatic infection and 78% (95% CI: 41–92) against medically attended infection. During the
102	Omicron BA.1/BA.2-predominant period (January–March 2022), rVE of a CoronaVac booster was 60%
103	(95% CI: 25–79) against symptomatic infection and 79% (95% CI: 44–92) against medically attended
104	COVID-19 (Figure 2, Table 2). Relative VE against symptomatic infection was 50% (95% CI: -3–75) 7-89
105	days post-booster, 67% (95% CI: 35–83) 90-149 days post-booster, and 48% (95% CI: -190–91) ≥150
106	days post-booster during the whole study period. (Figure 2, Table 2).
107	

108 Conclusions

109	Among HCWs in Azerbaijan, a CoronaVac booster dose offered additional protection against
110	symptomatic infection and medically attended infection compared to CoronaVac PVS during an
111	Omicron period. This protection, which lasted at least five months, occurred in a cohort that already
112	had rates of prior infection approaching 70% in mid-2021 (9), highlighting the importance of the
113	booster dose in reducing COVID-19 morbidity, even among HCWs with high rates of previous infection.
114	The importance of the booster dose is relevant for the general population of Azerbaijan too, where
115	COVID-19 PVS uptake is 47% and booster dose uptake is 34% (12).
116	Other studies have found variable rVE and absolute VE of a CoronaVac booster dose. A Brazilian
117	study estimated a lower rVE of booster CoronaVac against symptomatic disease of 5% at 8-59 days
118	after receipt; rVE subsequently declined to zero after 60 days in that study (5). Uncontrolled bias may
119	have contributed to the low and negative estimates against symptomatic infection in that study (13).
120	The same study estimated an rVE of booster CoronaVac against hospitalization of 47% during the same
121	time period (5). In Hong Kong, in a mainly infection-naïve population, estimated absolute VE of
122	CoronaVac booster against symptomatic BA.2 infection was 42% (3). In Brazil, in a population with
123	higher seroprevalence, absolute VE of a CoronaVac booster dose was 9% (5); in another Brazilian study,
124	CoronaVac booster dose absolute VE was 38% among persons with previous infection (7). CoronaVac
125	booster absolute VE against severe disease during Omicron BA.1/BA.2 period was high in studies in
126	both Hong Kong Special Administrative Region (85%) (4)and Brazil (74%) (5).
127	The strengths of our study include its prospective cohort design and close follow-up of
128	participants. Moreover, this is one of few studies to evaluate inactivated COVID-19 vaccine in the WHO
129	European Region. Our study also had limitations. The precision of rVE estimates was limited because of
130	the low number of events. We could not measure absolute VE of a COVID-19 booster because of the

- 131 small number of unvaccinated participants. We were not powered to estimate VE against severe
- 132 outcomes like hospitalization and death. Most infections occurred during Omicron BA.1/BA.2
- 133 circulation, so VE estimates should be understood in that context.
- 134 In conclusion, our results highlight the additional preventive benefit of CoronaVac booster vaccine
- 135 against symptomatic and medically attended infection and provide evidence to encourage uptake of
- 136 future booster doses among HCWs and the general population in Azerbaijan.

137

- 138 Iris Finci is infectious disease epidemiologist. She is currently a consultant epidemiologist in WHO
- 139 Regional Office for Europe coordinating COVID-19 and influenza vaccine effectiveness studies in
- 140 European region. Her primary research interests include viral respiratory infections, tuberculosis and
- 141 strengthening of disease surveillance.
- 142

143 Author contributions

144 GH, MAK, NS, SM, and RP conceived the cohort study on which this analysis is based. MAK, LD, NS, SM, 145 CJM, RP, GH, MYRC, and EK planned and implemented the study, including the development of study 146 protocols, data guality checks, and acquisition of data. IF, NS and MAK conceived the article. IF and NS 147 drafted the manuscript and performed the literature search. MYRC performed the data analysis with 148 support from EK. SM, MYRC and EK directly accessed and verified the raw data and take responsibility 149 for the integrity and accuracy of the analyses. BM and CD performed sequencing of study samples. All 150 authors contributed to the interpretation of the results and critically revised the manuscript. All 151 authors had full access to all the data reported in the study and accept responsibility to submit the 152 paper for publication.

153

154 Acknowledgements

155	Javahir Suleymanova (World Health Organization, Country Office Azerbaijan), Alina Guseinova,
156	Radu Cojocaru (World Health Organization, Regional Office for Europe, Denmark), Trent M. Herdman,
157	Jason Doran (UK Field Epidemiology Training Programme, United Kingdom), Caleb Ward (US Centers
158	for Disease Control, Georgia), Kathryn Lafond (US Centers for Disease Control, USA), Jörn Beheim-
159	Schwarzbach, Victor M. Corman, and Terry C. Jones (Institute of Virology, Charité-Universitätsmedizin
160	Berlin, corporate member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin
161	Institute of Health, Berlin, Germany; and German Centre for Infection Research (DZIF), partner site
162	Charité, Berlin, Germany); Marta Valenciano and Alain Moren (Epiconcept, France).The Sorgular.az
163	platform was developed by the Public Health and Reform Center of the Azerbaijan Ministry of Health
164	with support from the United Nations Development Program and United Nations Population Fund.
165	
166	Disclaimer
167	The findings and conclusions in this report are those of the author(s) and do not necessarily represent
168	the views of the Centers for Disease Control and Prevention. The authors affiliated with the World
169	Health Organization (WHO) are alone responsible for the views expressed in this publication and they
170	do not necessarily represent the decisions or policies of the WHO.
171	
172	Financial statement

173 This study was funded by The Task Force for Global Health and World Health Organisation Regional174 Office for Europe.

175

176 **Conflict of interest**

- 177 None of the authors have conflict of interest.
- 178

179 References

- 180 1. Meslé MM, Brown J, Mook P, Hagan J, Pastore R, Bundle N, et al. Estimated number of deaths
- directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO
- 182 European Region, December 2020 to November 2021. Euro Surveill Bull Eur sur les Mal Transm
- 183 = Eur Commun Dis Bull. 2021 Nov;26(47).
- 184 2. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of
- 185 COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis [Internet].
- 186 2022;22(9):1293–302. Available from: http://dx.doi.org/10.1016/S1473-3099(22)00320-6
- 187 3. Tsang NNY, So HC, Cowling BJ, Leung G, Ip DKM. Effectiveness of BNT162b2 and CoronaVac
- 188 COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron
- 189 BA.2 in Hong Kong: a prospective cohort study. Lancet Infect Dis [Internet]. 2023;23(4):421–34.
- 190 Available from: http://dx.doi.org/10.1016/S1473-3099(22)00732-0
- 191 4. Wei Y, Jia KM, Zhao S, Hung CT, Mok CKP, Poon PKM, et al. Estimation of Vaccine Effectiveness
- 192 of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-
- 193 CoV-2 Omicron. JAMA Netw Open. 2023;6(2):1–13.
- 194 5. Ranzani OT, Hitchings MDT, de Melo RL, de França GVA, Fernandes C de FR, Lind ML, et al.
- 195 Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters
- against Omicron in Brazil. Nat Commun. 2022;13(1):1–10.

- 197 6. Huang Z, Xu S, Liu J, Wu L, Qiu J, Wang N, et al. Effectiveness of inactivated COVID-19 vaccines
- among older adults in Shanghai: retrospective cohort study. Nat Commun. 2023;14(1):2009.
- 199 7. Cerqueira-Silva T, de Araujo Oliveira V, Paixão ES, Florentino PTV, Penna GO, Pearce N, et al.
- 200 Vaccination plus previous infection: protection during the omicron wave in Brazil. Lancet Infect
- 201 Dis. 2022;22(7):945–6.
- 8. Johns Hopkins Bloomberg School of Public Health. International Vaccine Access Center (IVAC)
- 203 [Internet]. 2023 [cited 2023 Jul 4]. Available from: https://view-
- 204 hub.org/vaccine/covid/effectiveness-studies
- 205 9. Katz MA, Rojas Castro MY, Seyidov N, Herdman MT, Mehdiyev S, McKnight CJ, et al. The
- 206 effectiveness of primary series CoronaVac vaccine in preventing COVID-19 illness: A prospective
- 207 cohort study among healthcare workers in Azerbaijan, May–November 2021. Influenza Other
- 208 Respi Viruses [Internet]. 2023;17(10):e13147. Available from:
- 209 https://onlinelibrary.wiley.com/doi/abs/10.1111/irv.13147
- 210 10. World Health Organization Regional Office for Europe. Cohort study to measure COVID-19
- 211 vaccine effectiveness among health workers in the WHO European Region: guidance document.
- 212 World Health Organization. Regional Office for Europe; 2021.
- 213 11. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data from vision to reality.
- 214 Eurosurveillance [Internet]. 2017;22(13). Available from:
- 215 https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.13.30494
- 216 12. WHO Regional Office for Europe. WHO/Europe COVID-19 Vaccine Programme Monitor
- 217 [Internet]. Available from: https://worldhealthorg.shinyapps.io/EURO_COVID-
- 218 19_vaccine_monitor/

- 219 13. Bodner K, Irvine MA, Kwong JC, Mishra S. Observed negative vaccine effectiveness could be the
- canary in the coal mine for biases in observational COVID-19 studies [Internet]. Vol. 131,
- 221 International Journal of Infectious Diseases. 2023. p. 111–4. Available from:
- 222 https://pubmed.ncbi.nlm.nih.gov/33276180/
- 14. World Health Organisation. WHO COVID-19 Dashboard [Internet]. 2023. Available from:
- 224 https://covid19.who.int/
- 225
- 226
- 227
- •••
- 228
- 229

230Table 1. Demographic and occupational characteristics of health care worker participants by vaccination231status on the first day of the follow-up period (n=1367), Azerbaijan, 2022

	All Participants, N=1367	Unvaccinated, N=23	Partially vaccinated (one dose), N=30	Vaccinated with primary vaccine series (two doses), N=375	Vaccinated with booster dose (third dose), N=939
Age, N=1367					
Median (IQR)	48 (39-57)	51 (37-62.5)	43 (35-58.8)	47 (38-56)	49 (40-57)
Age group, years, N=1367					
20-29, n (%)	73 (5)	3 (13)	1 (3)	29 (8)	40 (4)
30-39, n (%)	290 (21)	6 (26)	12 (40)	84 (22)	188 (20)
40-49, n (%)	371 (27)	2 (9)	4 (13)	96 (26)	269 (29)
50-59, n (%)	416 (30)	4 (17)	8 (27)	110 (29)	294 (31)
60+, n (%)	217 (16)	8 (35)	5 (17)	56 (15)	148 (16)
Sex, N=1367					
M, n (%)	91 (7)	1 (4)	4 (13)	21 (6)	65 (7)
F, n (%)	1276 (93)	22 (96)	26 (87)	354 (94)	874 (93)
Hospital, N=1367					
Hospital 7, n (%)	269 (20)	4 (17)	2 (7)	40 (11)	223 (24)
Hospital 15, n (%)	122 (9)	0 (0)	1 (3)	8 (2)	113 (12)
Hospital 18, n (%)	204 (15)	1 (4)	3 (10)	56 (15)	144 (15)
Hospital 23, n (%)	95 (7)	3 (13)	6 (20)	29 (8)	57 (6)
Hospital 24, n (%)	191 (14)	6 (26)	5 (17)	82 (22)	98 (10)

Hespital 28, n (%)369 (2)2 (9)10 (33)107 (29)24 (24) (25)Hospital 28, n (%)127 (9)7 (30)3 (10)53 (14)64 (7)Hospital Location, N=13677 (30)9 (30)146 (39)355 (38)Sub-urban, n (%)850 (62)16 (70)21 (70)229 (61)544 (62)Occupation/Role in hospital N=13FFF346 (37)10 (37)142 (38)364 (37)Marked Dottor, n (%)349 (26)7 (30)8 (27)101 (27)233 (25)Other, n (%)349 (26)7 (30)11 (37)132 (35)360 (38)BMI, N=1367FFFFFUnderweight or normal, n (%)382 (28)8 (35)6 (20)110 (29)256 (27)Oresweight, n (%)590 (37)9 (39)7 (23)129 (34)364 (39)Obese, n (%)476 (35)6 (20)17 (57)136 (36)317 (34)Smoking, N=1367FFFFCurrently smokes, n (%)14 (16)1 (4)1 (3)6 (27)9 (30)Never smokes, n (%)14 (16)14 (61)14 (47)12 (57)560 (52)Smoked pervisions, n (%)14 (10)9 (39)16 (53)163 (43)559 (32)Number of chonic condition, N=1367FFFFN, n (%)80 (90)14 (16)14 (47)12 (57)560 (52)2, n (%)90 (30)12 (30)16 (53)163 (43)559 (52)2, n (%)90 (50) <t< th=""><th></th><th></th><th></th><th></th><th></th><th></th></t<>											
<table-container>Hospital Location, N=1397Unban, n(%)570 (30)9 (30)14 (39)365 (30)Sub-urban, n(%)565 (37)7 (30)11 (37)142 (38)464 (37)Medical Doctor, n(%)50 (37)7 (30)8 (37)101 (37)33 (32)Medical Doctor, n(%)52 (37)9 (30)11 (37)132 (35)33 (32)Other, n(%)52 (37)9 (30)11 (37)132 (35)36 (37)Duban, n(%)52 (37)9 (30)7 (33)10 (27)36 (37)Overweight on normal, n(%)382 (28)8 (35)6 (20)110 (29)258 (27)Overweight, n(%)509 (37)9 (39)7 (23)120 (40)364 (20)Overweight, n(%)509 (37)9 (39)7 (23)120 (40)364 (20)Overweight, n(%)13 (50)1 (4)1 (3)60 (30)10 (30)Nore sonkea, n(%)13 (4)1 (3)60 (80)80 (80)Nore sonkea, n(%)13 (4)1 (3)16 (30)36 (30)Nore sonkea, n(%)13 (4)1 (3)16 (30)36 (30)No n(%)20 (60)1 (30)16 (50)10 (30)36 (30)No n(%)80 (30)1 (4)1 (4)1 (3)9 (30)No n(%)80 (30)1 (4)1 (4)1 (3)9 (30)No n(%)80 (30)1 (50)1 (4)1 (3)9 (30)No n(%)80 (30)1 (50)1 (4)1 (3)9 (30)No n(%)80 (30)1 (50)1 (4)1</table-container>	Hospital 26, n (%)	359 (26)	2 (9)	10 (33)	107 (29)	240 (26)					
<table-container>Han, n(%)517(38)7(30)9(30)146(39)355(38)Sub-uhn, n(%)80(62)16(70)21(70)229(61)64(62)GoupationRole in hospital, N-327(30)11(37)142(38)36(37)Media Dactor, n(%)349 (28)7(30)8(27)101 (27)233 (28)Other, n(%)312 (37)9(39)11(37)132 (38)36(37)BM, N-1367JJ100 (29)256(27)36(37)Overweight or normal, n(%)382 (28)8 (35)6 (20)100 (29)363 (29)Obese, n(%)476 (35)6 (20)17 (37)136 (36)364 (39)Obese, n(%)315 (96)27 (90)368 (90)368 (90)Smoke proviously, n(%)14 (10)10(3)6 (21)363 (28)Smoke proviously, n(%)14 (10)14 (47)13 (34)36 (30)Smoke proviously, n(%)14 (10)14 (47)13 (34)36 (32)Smoke proviously, n(%)40 (20)6 (20)50 (20)50 (20)Smoke proviously, n(%)14 (10)14 (47)14 (34)36 (32)Smoke proviously, n(%)14 (10)14 (10)14 (10)36 (30)Smoke proviously, n(%)14 (10)16 (30)36 (30)36 (30)Smoke proviously, n(%)16 (10)16 (30)16 (30)36 (30)Smoke proviously, n(%)16 (10)16 (30)16 (30)36 (30)Smoke proviously, n(%)16 (10)16 (30)16 (30)36 (30)Smoke proviously, n(%)<</table-container>		127 (9)	7 (30)	3 (10)	53 (14)	64 (7)					
<table-container>Sub-urban, n(%)880 (62)16 (70)21 (70)29 (81)584 (62)Nurse or Midwife, n(%)349 (63)7 (30)11 (37)14 (38)346 (37)Midecial Deckr, n(%)349 (23)8 (39)11 (37)12 (33)360 (38)Other, n (%)349 (25)8 (39)11 (37)12 (33)360 (38)Other, n (%)352 (28)8 (35)6 (20)110 (29)258 (27)Otherweight on normal, n (%)352 (28)8 (35)6 (20)110 (29)258 (27)Otherweight on normal, n (%)352 (28)8 (35)7 (23)129 (34)364 (39)Otherweight on normal, n (%)350 (27)9 (39)7 (23)129 (34)364 (39)Otherweight on normal, n (%)350 (27)9 (39)7 (23)136 (30)363 (39)Otherweight on normal, n (%)350 (27)9 (39)7 (23)160 (30)363 (39)Otherweight on normal, n (%)350 (27)2 (36)2 (30)363 (39)363 (39)Otherweight on normal, n (%)350 (27)2 (36)2 (36)363 (39)363 (39)Otherweight on normal, n (%)351 (39)3 (30)1 (31)363 (39)363 (39)Otherweight on normal, n (%)351 (49)3 (40)3 (30)36 (30)36 (30)Otherweight provide normal, n (%)350 (20)3 (30)1 (4 (47)1 (33)3 (30)3 (30)<td colsp<="" td=""><td></td><td></td><td>- ()</td><td>- ()</td><td></td><td> /</td></td></table-container>	<td></td> <td></td> <td>- ()</td> <td>- ()</td> <td></td> <td> /</td>			- ()	- ()		/				
Occupation/Robe in hospital, N=1 SUPNursee or Midwife, n (%)506 (37)7 (30)11 (37)142 (38)346 (37)Medical Doctor, n (%)612 (37)9 (30)8 (27)101 (23)233 (26)Other, n (%)512 (37)9 (30)8 (27)101 (21)233 (26)BMI, N=1357Underweight or normal, n (%)382 (28)8 (35)6 (20)110 (29)258 (27)Overweight, n (%)609 (37)9 (39)7 (23)129 (34)364 (39)Overweight, n (%)609 (37)9 (39)7 (23)136 (36)317 (34)Overweight, n (%)609 (37)9 (39)7 (23)136 (36)30 (3)Overweight, n (%)363 (30)14 (37)13 (30)6 (27)30 (30)Statistic Mathematical M		. ,									
<table-container>Nurse or Midwife, n(%)506 (37)7 (30)1 (137)142 (38)346 (37)Medical Doctor, n(%)349 (26)7 (30)8 (27)101 (27)233 (25)Other, n(%)512 (37)9 (30)1 (137)102 (7)303 (7)BM, H=337559 (37)9 (39)7 (23)129 (34)364 (37)Overweight or normal, n(%)580 (37)9 (39)7 (23)129 (34)364 (37)Obese, n(%)367 (35)6 (20)120 (36)364 (37)Obese, n(%)363 (37)1 (34)1 (37)163 (36)363 (37)Obese, n(%)38 (37)1 (4)1 (37)368 (89)363 (37)Newt smokes, n(%)38 (37)1 (4)1 (37)368 (89)363 (37)Newt smokes, n(%)38 (37)1 (4)1 (4)363 (89)360 (37)Newt or fortoric conditions, N=TN=TN=TN=TNo, n(%)520 (60)1 (61)1 (4)12 (57)580 (52)10, n(%)820 (60)1 (4 (51)14 (47)12 (57)580 (52)21, n(%)83 (28)1 (41)10 (33)104 (28)26 (28)21, n(%)500 (39)1 (52)1 (52)174 (49)36 (39)24, n(%)500 (39)1 (52)1 (52)1 (41)1 (30)1 (41)21, n(%)500 (39)1 (53)1 (52)1 (52)1 (52)1 (52)21, n(%)500 (53)1 (52)1 (52)1 (52)1 (52)1 (52)1 (52)21, n(%)500 (53</table-container>			16 (70)	21 (70)	229 (61)	584 (62)					
<table-container>Medical Doctor, n(%)349 (26)7 (30)8 (27)10 107,233 (25)Other, n (%)512 (37)9 (39)11 (37)132 (35)360 (38)BHALSOFUnderweight or normal, n(%)382 (28)8 (35)6 (20)110 (29)256 (27)Overweight, n (%)369 (37)9 (39)7 (23)129 (34)364 (39)Overweight, n (%)369 (37)6 (20)136 (36)317 (34)Overweight, n (%)369 (37)14 (3136 (36)317 (34)Overweight, n (%)315 (36)22 (96)27 (90)368 (98)98 (98)Overweight, n (%)315 (36)22 (96)27 (90)368 (98)369 (38)Sol (26)14 (41)14 (47)12 (57)50 (62)Sol (26)26 (96)14 (61)14 (47)12 (57)50 (62)Over molecondition, N=132*UOver molecondition, N=132*Over molecondition, N=132*<!--</td--><td colspan="11"></td></table-container>											
Other, n (%) 512 (37) 9 (39) 11 (37) 132 (35) 360 (38) BMI, N=1367 J		506 (37)			142 (38)	346 (37)					
BH, N=1367 Underweight or normal, n(%) 382 (28) 8 (35) 6 (20) 110 (29) 25 (27) Overweight, n(%) 509 (37) 9 (39) 7 (23) 120 (34) 364 (39) Overweight, n(%) 47 (63) 6 (20) 7 (23) 136 (36) 317 (34) Obese, n(%) 47 (30) 6 (20) 7 (90) 36 (30) 317 (30) Never smokes, n(%) 131 (96) 22 (96) 27 (90) 36 (89) 398 (96) Smoke previously, n(%) 131 (96) 22 (96) 27 (90) 36 (30) 36 (32) Any Arbert Condition, N=157 V V 12 (257) 580 (62) 36 (32) Yes, n(%) 420 (60) 14 (61) 14 (47) 12 (257) 580 (62) Ye, n(%) 362 (20) 14 (61) 14 (47) 12 (257) 580 (62) Ye, n(%) 363 (28) 17 (10) 104 (28) 26 (62) 24 (17) 10 (33) 104 (28) 36 (62) Ye, n(%) 500 (39) 12 (55) 10 (34) 136 (39)	Medical Doctor, n (%)	349 (26)	7 (30)	8 (27)	101 (27)	233 (25)					
Inderweight or normal, n (%)382 (28)8 (35)6 (20)110 (29)258 (27)Overweight, n (%)509 (37)9 (39)7 (23)129 (34)364 (39)Obese, n (%)4 (6 (5)0 (23)129 (34)364 (39)Smoking, N-1367UU1 (3)6 (2)30 (3)Currently smokes, n (%)3 (3)2 (29)2 (90)368 (98)98 (96)Smoked previously, n (%)14 (1)0 (0)2 (7)1 (<1)	Other, n (%)	512 (37)	9 (39)	11 (37)	132 (35)	360 (38)					
<table-container>Overweight, n (%)509 (37)9 (39)7 (23)129 (34)364 (39)Obese, n (%)47 (35)6 (26)7 (57)136 (36)317 (34)Banking, N=1367Banking, N=136722 (96)27 (90)6 (80 (80)808 (80)808 (80)Banking, N(%)1315 (96)22 (90)27 (90)868 (80)808 (80)808 (80)Banking, N(%)1315 (96)20 (90)2 (7 (90)868 (80)808 (80)808 (80)Banking, N(%)20 (60)14 (61)14 (47)212 (57)580 (62)Any Chronic condition, N=7VVNo, n(%)820 (60)14 (61)14 (47)212 (57)580 (62)A (14)212 (57)580 (62)A (14)212 (57)680 (62)A (14)14 (12)216 (75)880 (62)A (14)14 (17)212 (57)880 (62)A (14)14 (12)216 (75)880 (62)A (14)14 (12)216 (75)880 (62)A (14)14 (12)71 (40)450 (52)A (14)14 (12)71 (40)450 (52)A (14)14 (12)71 (40)450 (52)A (14)14 (12)71 (40)73 (40)A (15)15 (14)15 (14)15 (14)15 (14)A (15)16 (14)16 (16)<</table-container>	BMI, N=1367										
<table-container>Overweight, n (%)509 (37)9 (39)7 (23)129 (34)364 (39)Obese, n (%)47 (35)6 (26)7 (57)136 (36)317 (34)Banking, N=1367Banking, N=136722 (96)27 (90)6 (80 (80)808 (80)808 (80)Banking, N(%)1315 (96)22 (90)27 (90)868 (80)808 (80)808 (80)Banking, N(%)1315 (96)20 (90)2 (7 (90)868 (80)808 (80)808 (80)Banking, N(%)20 (60)14 (61)14 (47)212 (57)580 (62)Any Chronic condition, N=7VVNo, n(%)820 (60)14 (61)14 (47)212 (57)580 (62)A (14)212 (57)580 (62)A (14)212 (57)680 (62)A (14)14 (12)216 (75)880 (62)A (14)14 (17)212 (57)880 (62)A (14)14 (12)216 (75)880 (62)A (14)14 (12)216 (75)880 (62)A (14)14 (12)71 (40)450 (52)A (14)14 (12)71 (40)450 (52)A (14)14 (12)71 (40)450 (52)A (14)14 (12)71 (40)73 (40)A (15)15 (14)15 (14)15 (14)15 (14)A (15)16 (14)16 (16)<</table-container>											
<table-container>Desen (%)476 (35)6 (26)17 (77)13 (30)17 (34)Service (%)Service (%)<tr< td=""><td>Underweight or normal, n (%)</td><td>382 (28)</td><td>8 (35)</td><td>6 (20)</td><td>110 (29)</td><td>258 (27)</td></tr<></table-container>	Underweight or normal, n (%)	382 (28)	8 (35)	6 (20)	110 (29)	258 (27)					
<table-container>Smoking, N=1367Currently smokes, n (%)38 (3)1 (4)1 (3)6 (2)30 (3)Never smokes, n (%)1315 (96)22 (96)27 (90)368 (98)988 (96)Smoked previously, n (%)14 (1)0 (0)2 (7)1 (-1)11 (1)Anyertonic condition, N=1367580 (60)14 (417)212 (57)580 (62)Yes, n (%)647 (40)9 (39)16 (53)163 (43)256 (28)Yes, n (%)820 (60)14 (61)14 (47)212 (57)580 (62)1, n (%)383 (28)4 (17)10 (33)104 (28)265 (28)2, n (%)164 (12)52)6 (20)59 (16)340 (39)1, n (%)383 (28)4 (17)10 (33)104 (28)265 (28)2, n (%)600 (39)12 (55)10 (34)138 (39)340 (39)45, n (%)650 (39)12 (50)10 (34)138 (39)340 (39)45, n (%)650 (39)12 (50)174 (49)459 (52)26, n (%)126 (10)4 (18)18 (60)200 (53)566 (60)Yes, n (%)798 (58)14 (61)18 (60)201 (53)560 (91)Yes, n (%)593 (14)19 (83)12 (40)131 (23)80 (91)1, n (%)114 (81)19 (83)12 (40)132 (28)80 (91)1, n (%)150 (150-187)150 (150-187)150 (150-187)150 (150-187)Delay betwee 2nd dose and start114 (81)19 (83)12 (40)12 (30)39 (16)<t< td=""><td>Overweight, n (%)</td><td>509 (37)</td><td>9 (39)</td><td>7 (23)</td><td>129 (34)</td><td>364 (39)</td></t<></table-container>	Overweight, n (%)	509 (37)	9 (39)	7 (23)	129 (34)	364 (39)					
<table-container>Currently mokes, n(%)38 (3)1(4)1(3)6(2)303()Never smokes, n(%)1315 (96)22 (96)27 (90)368 (98)898 (96)Smoked previously, n(%)14 (17)20 (70)1 (41)11 (1)Ary chronic condition, N=136"547 (40)90 (80)16 (41)212 (57)580 (62)Yes, n(%)547 (40)16 (53)16 (53)16 (34)580 (62)Yes, n(%)547 (40)14 (47)121 (57)580 (62)Yes, n(%)383 (28)4 (17)10 (33)104 (28)262 (28)2, n(%)363 (28)4 (17)10 (33)104 (28)263 (28)2, n(%)164 (12)5 (22)6 (20)59 (16)94 (10)Yes, n(%)500 (39)12 (55)174 (49)459 (52)2, n(%)500 (39)12 (55)174 (49)459 (52)2, n(%)64 (51)6 (27)15 (52)174 (49)459 (52)2, n(%)509 (39)12 (40)176 (49)37 (40)45, n(%)509 (39)12 (40)176 (47)37 (40)Yes, n(%)58 (58)4 (17)18 (60)20 (53)56 (60)Yes, n(%)58 (59)14 (13)18 (60)20 (53)56 (60)Yes, n(%)58 (59)12 (40)18 (60)13 (40)16 (10)Yes, n(%)59 (59)12 (40)18 (60)30 (9)Yes, n(%)59 (59)12 (40)18 (60)16 (50)Yes, n(%)59 (59)12 (40)18 (60)16 (</table-container>	Obese, n (%)	476 (35)	6 (26)	17 (57)	136 (36)	317 (34)					
<table-container>Never smokes, n(%)1315 (96)22 (96)27 (90)368 (98)898 (96)Smoked previously, n(%)14 (1)002711 (1)11 (1)Arr chronic condition, N=136"320 (60)4 (4 (61)14 (47)12 (2 (57)580 (62)Yes, n(%)247 (40)93014 (47)12 (2 (57)580 (62)Number of chronic conditions, N=T7580 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2</table-container>	Smoking, N=1367										
<table-container>Never smokes, n(%)1315 (96)22 (96)27 (90)368 (98)898 (96)Smoked previously, n(%)14 (1)002711 (1)11 (1)Arr chronic condition, N=136"320 (60)4 (4 (61)14 (47)12 (2 (57)580 (62)Yes, n(%)247 (40)93014 (47)12 (2 (57)580 (62)Number of chronic conditions, N=T7580 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2</table-container>	Currently smokes, n (%)	38 (3)	1 (4)	1 (3)	6 (2)	30 (3)					
Smoked previously, n (%)14 (1)0 (0)2 (7)1 (<1)11 (1)Any chronic condition, N=1367No, n (%)820 (60)14 (61)14 (47)212 (57)580 (62)Yes, n (%)547 (40)9 (39)16 (53)163 (43)359 (38)Number of chronic conditions, N=1367UUU10 (33)104 (28)265 (28)22, n (%)164 (12)5 (22)6 (20)59 (16)94 (10)Number of household members, N=1267UUU1-3, n (%)500 (39)12 (55)10 (34)138 (39)340 (39)4-5, n (%)654 (51)6 (27)15 (52)174 (49)459 (52)26, n (%)126 (10)4 (18)4 (14)14 (12)77 (9)Hands on care, N=1367UUUUUNo, n (%)798 (58)14 (61)18 (60)200 (53)566 (60)Yes, n (%)599 (42)9 (39)12 (40)175 (47)373 (40)Previous COVID-19 PCR confirmed intertion, N=1367UUUI, n (%)253 (19)4 (17)18 (60)203 (52)850 (91)I, n (%)305 (183-313)150 (150-187)309 (274-316)Delay between 3rd dose and statu $U=U (aux), N=339$ U $U=U (aux), N=330$ Coronal (QR)65 (65-92) $Coronal (aux), N=330$ $Coronal (aux), N = 330 (100)$ $Coronal (aux), N = 330 (100)$ Unvaccinated $Q3 (2)$ $Q3 (100)$ $Q3 (100)$ $Q3 (100)$ $Q3 (100)$	• • • •										
Any chronic condition, N=1367No, n (%)820 (60)14 (61)14 (47)212 (57)580 (62)Yes, n (%)547 (40)9 (39)16 (53)163 (43)359 (38)Number of chronic conditions, N=1367U0, n (%)820 (60)14 (61)14 (47)212 (57)580 (62)1, n (%)383 (28)4 (17)10 (33)104 (28)265 (28)22, n (%)164 (12)5 (22)6 (20)59 (16)94 (10)Number of household members, N=120U1-3, n (%)500 (39)12 (55)10 (34)138 (39)340 (39)4-5, n (%)500 (39)12 (57)15 (52)174 (49)459 (52)26, n (%)126 (10)4 (18)4 (14)41 (12)77 (9)Hands on care, N=1367No, n (%)798 (58)14 (61)18 (60)200 (53)566 (60)Yes, n (%)798 (58)14 (61)18 (60)203 (52)850 (91)Oti n (%)1114 (81)19 (83)12 (40)132 (32)89 (92)Delay between 2nd dose and startFollow-up (das: 13)Oti n (%)305 (183 -31)12 (40)130 (162)89 (92)Delay between 3nd cose and startFollow-up (das: 13)150 (150 -187)80 (92)Delay between 2nd cose and startDelay between 2nd cose and startDelay between 3											
<table-container>No. n (%)§20 (60)14 (61)14 (47)212 (57)830 (62)Yes, n (%)§47 (40)9 (39)16 (53)16 (34)359 (38)Horna conditions.Jer (%)§20 (60)14 (61)14 (47)212 (57)580 (62)1, n (%)383 (28)4 (17)10 (33)104 (28)265 (28)2, n (%)164 (12)5 (22)6 (20)59 (16)94 (10)Attemption foutschold members.U13, n (%)500 (39)12 (55)10 (34)138 (39)340 (39)45, n (%)500 (39)12 (55)10 (34)138 (39)459 (52)26 (30)12 (51)15 (52)17 (49)459 (52)26 (30)12 (51)15 (52)17 (49)459 (52)26 (30)16 (10)15 (20)17 (49)459 (52)Attemption for (%)16 (10)16 (10)17 (49)36 (60)Attemption for (%)16 (10)16 (10)17 (49)36 (60)Attemption for (%)16 (10)16 (10)16 (10)16 (10)Attemption for (%)16 (10)16 (10)16 (10)<td></td><td></td><td>0 (0)</td><td>2(1)</td><td>1 ((1)</td><td></td></table-container>			0 (0)	2(1)	1 ((1)						
Yes, n(%)§47 (40)9 (39)16 (53)163 (43)359 (38)Humber of horonic conditions, WWWState (53)State (53)0, n(%)820 (60)14 (61)14 (47)212 (57)580 (62)2, n (%)164 (12)5 (22)6 (20)59 (16)94 (10)2, n (%)164 (12)5 (22)6 (20)59 (16)94 (10)Humber of household members/UU13, n (%)500 (39)12 (55)10 (34)138 (39)340 (39)4.5, n (%)654 (51)6 (27)15 (52)174 (49)459 (52)26, n (%)569 (23)16 (16)174 (49)459 (52)UNo, n (%)569 (23)16 (16)175 (20)566 (62)On (%)198 (16)18 (60)200 (53)563 (63)U19 (83)12 (40)130 (30)560 (91)(10, %)19 (83)12 (40)132 (32)650 (91)On (%)19 (18)19 (83)12 (40)130 (30)50 (91)On (%)19 (13)19 (13)19 (13)19 (13)19 (13)On (%)19 (13)19 (13)19 (13)19 (13)19 (13)On (%)19 (13)19 (13)19 (13)19 (13)19 (13)On (%)19 (13)19 (13)19 (13)19 (13)On (%)19 (13)19		820 (60)	14 (61)	14 (47)	212 (57)	580 (62)					
Number of chronic conditions, N=1SUP0, n (%)820 (60)14 (61)14 (47)212 (57)580 (62)1, n (%)383 (28)4 (17)10 (33)104 (28)265 (28)22, n (%)164 (12)5 (22)6 (20)59 (16)94 (10)Number of household members, N=USUP1-3, n (%)500 (39)12 (55)10 (34)138 (39)340 (39)4-5, n (%)654 (51)6 (27)15 (52)174 (49)459 (52)26, n (%)126 (10)4 (18)4 (14)41 (12)77 (9)Hands on care, N=1367No, n (%)798 (58)14 (61)18 (60)200 (53)566 (60)Yeige colspan="2">Set (11)On (%)1114 (81)19 (83)12 (40)233 (62)850 (91)A (11)114 (81)19 (83)12 (40)233 (62)850 (91)A (11)114 (81)19 (83)12 (40)233 (62)850 (91)A (11)114 (81)19 (83)12 (40)23 (62)850 (91)A (12)253 (19)4 (17)18 (60)142 (38)89 (92)Diago total colspan="2">Set (12)50 (15)A (10)51 (13)51 (13)51 (13)51 (13)A (10)51 (13)51 (13)51 (13)51 (13)A (10)51 (13)51 (13)51 (13)51 (13)A (10)51 (13)51 (13)											
0, n (%)820 (60)14 (61)14 (47)212 (57)830 (62)1, n (%)383 (28)4 (17)10 (33)104 (28)265 (28)2, n (%)164 (12)5 (22)6 (20)59 (16)94 (10)Human subsection and the			- ()			(,					
1, n (%)383 (28)4 (17)10 (33)104 (28)265 (28)≥2, n (%)164 (12)5 (22)6 (20)59 (16)94 (10)Humber of household members.1-3, n (%)500 (39)12 (55)10 (34)138 (39)340 (39)4-5, n (%)654 (51)6 (27)15 (52)174 (49)459 (52)≥6, n (%)12 (61)4 (18)4 (14)14 (12)77 (9)Hands on care, N=1367Yes, n (%)98 (58)14 (61)18 (60)200 (53)566 (60)Yes, n (%)69 (42)9 (39)12 (40)233 (62)860 (7)Previous COVID-19 PCR confirmetor1114 (81)19 (83)12 (40)133 (62)850 (91)1, n (%)1114 (81)19 (83)12 (40)142 (38)89 (92)Charlen total			14 (61)	14 (47)	212 (57)	580 (62)					
≥2, n %)164 (12)5 (22)6 (20)59 (16)94 (10)Humber of household members,		. ,									
Number of household members, J=280 1-3, n (%) 500 (39) 12 (55) 10 (34) 138 (39) 340 (39) 4-5, n (%) 654 (51) 6 (27) 15 (52) 174 (49) 459 (52) 26, n (%) 12 (61) 4 (18) 4 (14) 412 (20) 77 (9) Hands on care, N=1367 V V 77 (9) No, n (%) 798 (58) 14 (61) 18 (60) 200 (53) 566 (60) Yes, n (%) 696 (42) 9 (39) 12 (40) 175 (47) 373 (40) Previous COVID-19 PCR confirmetretterton, N=1367 142 (38) 89 (9) 385 (19) 11 (1 (81) 19 (83) 12 (40) 233 (62) 850 (91) 1, n (%) 1114 (81) 19 (83) 12 (40) 233 (62) 850 (91) 1, n (%) 305 (183-313) 14 (21) 80 (92) 12 (40) 142 (38) 89 (92) Edelay between 2nd dose and start Follow-up (task) 142 (38) 30 (92 (54)) 160 (56) Cololay to tham (10R) 305 (183-313)		. ,	. ,								
1-3, n (%)500 (39)12 (55)10 (34)138 (39)340 (39)4-5, n (%)654 (51)6 (27)15 (52)174 (49)459 (52)≥6, n (%)126 (10)4 (18)4 (14)41 (12)77 (9)Hands on care, N=1367VVNo, n (%)798 (58)14 (61)18 (60)200 (53)566 (60)Yes, n (%)569 (42)9 (39)12 (40)175 (47)373 (40)Previous COVID-19 PCR confirmetretor, N=134'V0, n (%)1114 (81)19 (83)12 (40)233 (62)850 (91)1, n (%)253 (19)4 (17)18 (60)142 (38)89 (9)Iteleven 2nd dose and start/ Follow-up (day)V So (103)309 (274-316)Delay between 3rd dose and start/ Follow-up (day)150 (150-187)309 (274-316)COVID-19 vaccination status are traned to start to period start.150 (150-187)66 (56-92)Covidation factors and start to period start.Unvaccinated32 (2)32 (100)CoronaVac - 2 doses, n (%)375 (27)375 (100)GoronaVac - 3 doses, n (%)39 (69)39 (90)			- (<u></u>)	0 (20)	,	0. (10)					
$4-5$, n (%) 654 (51) 6 (27) 15 (52) 174 (49) 459 (52) ≥ 6 , n (%) 126 (10) 4 (18) 4 (14) 41 (12) 77 (9)Hands on care, N=1367No, n (%) 798 (58) 14 (61) 18 (60) 200 (53) 566 (60)Yes, n (%) 569 (42) 9 (39) 12 (40) 175 (47) 373 (40)Previous COVID-19 PCR confirmetrettor, N=1367Uraciona COVID-19 PCR confirmetrettor, N=1367Uraciona COVID-19 PCR confirmetrettor, N=1367J 99 (83) 12 (40) 233 (62) 850 (91) $1, n$ (%) 1114 (81) 99 (83) 12 (40) 233 (62) 850 (91) $1, n$ (%) 253 (19) 4 (17) 18 (60) 142 (38) 89 (9)Delay between 2nd dose and start to Ilow-up (day: N=3314)Delay between 3rd dose and start to Ilow-up (day: N=334)Delay colspan="4">Delay between 3rd dose and start to Ilow-up (day: N=344)Unvaccination status and Cis (Fig. 92) $Colspan= 100$ $S65$ (56-92) $Colspan= 100$ $S65$ (56-92) $S75$ (70) $S75$ (70) $S75$ (70) $S75$ (70) $S75$ (700)Corona Vac - 2 doses, n (%) 393 (69) $S10$ (S10) $S10$ (S10) $S15$ (S10) $S15$ (S10)Corona Vac - 3 doses, n (%) 393 (69) $S10$ (S10) $S10$ (S10) $S10$ (S10)			12 (55)	10 (34)	138 (39)	340 (39)					
≥6, n (%) 126 (10) 4 (18) 4 (14) 41 (12) 77 (9) Hands on care, N=1367											
Hands on care, N=1367No, n (%)798 (58)14 (61)18 (60)200 (53)566 (60)Yes, n (%)569 (42)9 (39)12 (40)175 (47)373 (40)Previous COVID-19 PCR confirmettiction, N=1367O, n (%)1114 (81)19 (83)12 (40)233 (62)850 (91)1, n (%)253 (19)4 (17)18 (60)142 (38)89 (9)Delay between 2nd dose and start follow-up (day: to 1305 (183-313)150 (150-187)309 (274-316)Delay between 3rd dose and start follow-up (day: to 1305 (183-313)150 (150-187)309 (274-316)Delay between 3rd dose and start follow-up (day: to 166 (56-92)150 (150-187)309 (274-316)Delay between 3rd dose and start follow-up (day: to 23 (20)150 (150-187)309 (274-316)Delay between 3rd dose and start follow-up (day: to 23 (20)150 (150-187)309 (274-316)Delay between 3rd dose and start follow-up (day: to 1305 (182-313)150 (150-187)309 (274-316)Delay between 3rd dose and start follow-up (day: to 18 (10R)66 (56-92)66 (56-92)66 (56-92)COVID-19 vaccination status and x: to x: to x: to x:315 (100)150 (100)CoronaVac - 2 doses, n (%)375 (27)375 (100)GronaVac - 3 doses, n (%)393 (69)393 (100)			. ,	. ,		. ,					
No, n (%)798 (58)14 (61)18 (60)200 (53)566 (60)Yes, n (%)569 (42)9 (39)12 (40)175 (47)373 (40) Previous COVID-19 PCR confirmetive N=131 0, n (%)1114 (81)19 (83)12 (40)233 (62)850 (91)1, n (%)253 (19)4 (17)18 (60)142 (38)89 (9) Delay between 2nd dose and start follow-up (day)Follow-up (day)Bedian (IQR)305 (183-313) I Sol (150-187) 309 (274-316) Delay between 3rd dose and start follow-up (day)1 150 (150-187)309 (274-316) Delay between 3rd dose and start follow-up (day)1111Bedian (IQR)66 (56-92) 111EVIDID-19 vaccination status23 (100) 11Corona Vac - 2 doses, n (%)375 (27) 3333333331Corona Vac - 3 doses, n (%)39 (69) 33333		- (-)	(-)	()	()	(-)					
Yes, n (%)569 (42)9 (39)12 (40)175 (47)373 (40)Previous COVID-19 PCR confirmetication, N=1360, n (%)1114 (81)19 (83)12 (40)233 (62)850 (91)1, n (%)253 (19)4 (17)18 (60)142 (38)89 (9)Delay between 2nd dose and statter follow-up (day: N=1314)Median (IQR)305 (183-313)150 (150-187)309 (274-316)Delay between 3rd dose and statter follow-up (day: N=1344)Median (IQR)66 (56-92)150 (150-187)66 (56-92)COVID-19 vaccination status and recipe trad at statter betrad at st		798 (58)	14 (61)	18 (60)	200 (53)	566 (60)					
Previous COVID-19 PCR confirmed infection, N=1367 0, n (%) 1114 (81) 19 (83) 12 (40) 233 (62) 850 (91) 1, n (%) 253 (19) 4 (17) 18 (60) 142 (38) 89 (9) Delay between 2nd dose and start of follow-up (days), N=1314 Median (IQR) 305 (183-313) 150 (150-187) 309 (274-316) Delay between 3rd dose and start of follow-up (days), N=939 Median (IQR) 66 (56-92) 66 (56-92) COVID-19 vaccination status and vaccine brand at start y period start, N=1367 Unvaccinated 23 (2) 23 (100) 375 (27) 575 (100) CoronaVac - 2 doses, n (%) 375 (27) 375 (100) 939 (100)											
0, n (%)1114 (81)19 (83)12 (40)233 (62)850 (91)1, n (%)253 (19)4 (17)18 (60)142 (38)89 (9)Delay between 2nd dose and start follow-up (day: N=1314Median (IQR)305 (183-313)150 (150-187)309 (274-316)Delay between 3rd dose and start follow-up (day: N=939)Median (IQR)66 (56-92)66 (56-92)66 (56-92)COVID-19 vaccination status and z: re brand at y period start, N=1367Unvaccinated23 (2)23 (100)75 (27)CoronaVac - 2 doses, n (%)375 (27)375 (100)375 (100)CoronaVac - 3 doses, n (%)939 (69)939 (100)939 (100)		· · /	, ,	12 (40)	110 (47)	575 (40)					
1, n (%)253 (19)4 (17)18 (60)142 (38)89 (9)Delay between 2nd dose and start of follow-up (days), N=1314Median (IQR) $305 (183-313)$ 150 (150-187)309 (274-316)Delay between 3rd dose and start of follow-up (days), N=939Median (IQR) $66 (56-92)$ 66 (56-92)66 (56-92)COVID-19 vaccination status and vaccine brand at vactine brand at		· · · · · ·		12 (40)	233 (62)	850 (01)					
Delay between 2nd dose and start of follow-up (days), N=1314Median (IQR) $305 (183-313)$ $150 (150-187)$ $309 (274-316)$ Delay between 3rd dose and start of low-up (days)N=939 $66 (56-92)$ $66 (56-92)$ Median (IQR) $66 (56-92)$ $66 (56-92)$ $66 (56-92)$ COVID-19 vaccination status and vertice brand at vertice brand at start, N=1367Unvaccinated $23 (2)$ $23 (100)$ CoronaVac - 2 doses, n (%) $375 (27)$ $375 (100)$ CoronaVac - 3 doses, n (%) $939 (69)$ $939 (100)$											
Median (IQR) $305 (183-313)$ $150 (150-187)$ $309 (274-316)$ Delay between 3rd dose and start of follow-up (days), N=939 $66 (56-92)$ $66 (56-92)$ Median (IQR) $66 (56-92)$ $66 (56-92)$ COVID-19 vaccination status and vaccine brand at study period start, N=1367 $150 (150-187)$ Unvaccinated $23 (2)$ $23 (100)$ CoronaVac - 2 doses, n (%) $375 (27)$ $375 (100)$ CoronaVac - 3 doses, n (%) $939 (69)$ $939 (100)$				18 (60)	142 (38)	89 (9)					
Delay between 3rd dose and start follow-up (days), N=939 Median (IQR) 66 (56-92) 66 (56-92) COVID-19 vaccination status and vaccine brand at vacuum brand vacuum brand at vacuum bran	•	• •	iys), N=1314								
Median (IQR) 66 (56-92) 66 (56-92) COVID-19 vaccination status and vertice brand at vert	· · ·	· · ·			150 (150-187)	309 (274-316)					
COVID-19 vaccination status and vaccine brand at study period start, N=1367 Unvaccinated 23 (2) 23 (100) CoronaVac - 2 doses, n (%) 375 (27) 375 (100) CoronaVac - 3 doses, n (%) 939 (69) 939 (100)			ys), N=939								
Unvaccinated 23 (2) 23 (100) CoronaVac - 2 doses, n (%) 375 (27) 375 (100) CoronaVac - 3 doses, n (%) 939 (69) 939 (100)		· · ·				66 (56-92)					
CoronaVac - 2 doses, n (%) 375 (27) 375 (100) CoronaVac - 3 doses, n (%) 939 (69) 939 (100)				art, N=1367							
CoronaVac - 3 doses, n (%) 939 (69) 939 (100)		. ,	23 (100)								
		. ,			375 (100)						
CoronaVac - 1 dose, n (%) 30 (2) 30 (100)		. ,				939 (100)					
	CoronaVac - 1 dose, n (%)	30 (2)		30 (100)							

232

233

Table 2. Relative COVID-19 vaccine effectiveness of CoronaVac booster dose compared to CoronaVac primary vaccine series againstsymptomatic and medically attended SARS-CoV-2 infection during a period of Omicron and relative vaccine effectiveness againstsymptomatic SARS-CoV-2 infection by time since receiving booster dose, Azerbaijan, January 1 – August 31, 2022

		N	Total person- time (days)	Symptomatic COVID-19 PCR- confirmed infections	Unadjusted HR	(95% CI)	Adjusted HR	(95% CI)	Relative vaccine effectiveness (%)	(95% CI)
ç	Full period (Jan-Aug 2022)	1306								
fectic	2 doses, ≥150d from 2nd dose	386	19964	16						
tic int	≥ 7d from 3rd dose	1184	232127	53	0.4	(0.7; 0.2)	0.4	(0.8; 0.2)	58.9	(24.3; 77.6)
Symptomatic infection	BA.1/BA.2 Omicron period (Jan-Mar 2022)	1253								
Sym	2 doses, ≥150d from 2nd dose ≥ 7d from 3rd dose	334	9221	15						
		1142	82575	48	0.4	(0.7; 0.2)	0.4	(0.8; 0.2)	60.1	(24.7; 78.8)
ection	Full period (Jan-Aug 2022) 2 doses, ≥150d from	1306								
ini bi	2nd dose	386	19964	8						
apue	≥ 7d from 3rd dose	1184	232127	15	0.2	(0.6; 0.1)	0.2	(0.6; 0.1)	77.7	(41.4; 91.5)
Medically attended infection	BA.1/BA.2 Omicron period (Jan-Mar 2022) 2 doses, ≥150d from	1253								
edic	2nd dose ≥ 7d from 3rd dose	334	9221	7						
	since vaccination	1142	82575	13	0.3	(0.6; 0.1)	0.2	(0.6; 0.1)	79.1	(43.5; 92.3)
Time					1		I		I	
	Full period (Jan-Aug 2022) 2 doses, ≥150d from	1306								
c	2nd dose	386	19964	16	Refere	ence	Refer	ence	Refere	ence
Symptomatic infection	7-89 days since 3rd dose 90-149 days since 3rd	929	42710	23	0.5	(1; 0.3)	0.5	(1; 0.2)	49.7	(-3.1; 75.4)
utic ir	dose	1104	59588	24	0.4	(0.7; 0.2)	0.3	(0.7; 0.2)	66.9	(35; 83.2)
toma	≥150 days since 3rd dose	1038	130127	6	0.5	(2.3; 0.1)	0.5	(2.9; 0.1)	48.2	(-190.3; 90.8)
Symp	BA.1/BA.2 Omicron period (Jan-Mar 2022) 2 doses, ≥150d from	1253								
	2nd dose	334	9221	15	Refere	ence	Refer	ence	Refere	ence
	7-89 days since 3rd dose	890	31828	22	0.4	(0.9; 0.2)	0.4	(0.9; 0.2)	55.1	(9.6; 77.7)

90-149 days since 3rd dose ≥150 days since 3rd	857	39158	24	0.4	(0.7; 0.2)	0.3	(0.7; 0.2)	67.1	(34.4; 83.5)	
dose	464	11848	2	0.6	(3.2; 0.1)	0.7	(3.6; 0.1)	34.8	(-261.5; 88.2)]

*All rVE estimates were adjusted by hospital site (urban or suburban) and previous PCR-confirmed SARS-CoV-2 infection; HR – hazard ratio




Figure 1. Number of symptomatic PCR-confirmed SARS-CoV-2 positive healthcare workers by vaccination status and symptom onset, and number of SARS-CoV-2 cases in Azerbaijan (14), January-August 2022




Figure 2. Relative vaccine effectiveness of a CoronaVac booster dose compared to CoronaVac primary series, Azerbaijan, 2022

Left panel – symptomatic SARS-CoV-2 infection, total rVE (red) and stratified by time since vaccination (blue); Right panel – medically attended SARS-CoV-2 infection. Star (*) indicates that the scale was cut off.